Le Lézard
Classified in: Health
Subjects: SVY, EGV

Two Day Veterinary Pharmaceutical Submissions in the EU Course: London, United Kingdom - November 20-21, 2018


DUBLIN, May 11, 2018 /PRNewswire/ -- The "Veterinary Pharmaceutical Submissions in the EU" conference has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Presentations will cover the regulatory framework, pharmaceutical, toxicological and pharmacological data, safety risk assessments, pre-clinical and clinical data, Detailed and Critical Summaries and regulatory submissions

Course Overview

This practical two-day In-house course will take participants through all of the constituent parts of the application for marketing authorisation for a veterinary medicinal product for which a marketing authorisation is sought in the European Union, including the Maximum Residue Limits dossier.

Presentations will cover the regulatory framework, pharmaceutical, toxicological and pharmacological data, safety risk assessments, pre-clinical and clinical data, Detailed and Critical Summaries and regulatory submissions. An important part of the course will be devoted to working on case studies in the workshop sessions. The course will provide a comprehensive introduction to the entire regulatory dossier for a veterinary medicinal product in the European Union.

BENEFITS OF ATTENDING

Who Should Attend:

Personnel working in the following departments: Regulatory Affairs, Research and Development and Clinical Trials and Marketing. It will also be valuable to those seeking to review special problems encountered in the registrations of veterinary medicines. There will be ample opportunity for discussion during the proceedings.

Agenda:

Programme Day One

09.30 Introduction and Objectives of the course

09.45 EU Regulatory Framework

10.45 Refreshments

11.00 Part II: Pharmaceutical Data Requirements

12.15 Discussion

12.30 Lunch

13.30 Workshop session

Planning a dossier to contain:

14.45 Part IIIA: Consumer and Environmental Safety Data Requirements

15.15 User Safety Risk Assessment

15.45 Refreshments

16.00 Pharmacokinetics and Bioequivalence

17.00 End of Day One

Programme Day Two

09.00 Environmental Risk Assessment

09.30 Part IIIB Residues

10.15 Safety and Residues' Detailed and Critical Summaries

10.30 Refreshments

10.45 Part IV Pre-Clinical Data

11.15 Part IV Clinical Data and Clinical' Detailed and Critical Summary

11.45 EU Regulatory Strategies and Procedures

12.30 Lunch

14.00 Workshop Session

15.00 Refreshments

15.15 Workshop Presentations

15.45 Writing the Regulatory Submission

16.45 Discussion

17.00 End of Course

For more information about this conference visit https://www.researchandmarkets.com/research/jj3kn8/two_day?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 16:20
Guardant Health, Inc. , a leading precision oncology company, today announced the company will participate in the following investor conferences. BofA Securities 2024 Healthcare Conference in Las Vegas Fireside Chat on Wednesday, May 15 at 10:40...

at 16:20
Biote , a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024...

at 16:20
Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024. "This was a quarter of clinical progress as we await key,...

at 16:15
Exelixis, Inc. today announced that members of the company's management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20...

at 16:15
Danaher Corporation announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024. ABOUT DANAHER     Danaher is a...

at 16:15
Cardinal Health announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the...



News published on and distributed by: